Adults and children suffering from attention-deficit hyperactivity disorder now have a treatment specifically indicated for them.
Atomoxetine (Strattera) is the first drug to receive Food and Drug Administration approval for the treatment of attention-deficit hyperactivity disorder (ADHD) in both adults and children. It is also the first new type of drug approved for the disorder in 3 decades.
Data from six double-blind trials presented to the FDA--with 697 patients taking atomoxetine, 427 of whom were children and adolescents--found the drug to be significantly more effective than placebo.
Because it is not a stimulant, atomoxetine dodges a controlled substances classification, unlike stimulant medications now prescribed for …